(AKTS) Aktis Oncology, Inc. Business Model Canvas Research

Aktis Oncology, Inc. depends on radioisotope suppliers and specialist logistics to secure short-lived materials like actinium-225, which has a 9.92-day half-life, and lutetium-177, at 6.65 days. Tight chain-of-custody control matters because any delay can slow trials, disrupt GMP manufacturing, and cap scale-up.

• Reliable isotope access
• Chain-of-custody control
• Trial and scale-up timing

Strategic pharma licensing partners could include large oncology players like Novartis, which reported $1.4 billion in Pluvicto sales in 2024, plus other radiopharma buyers seeking co-development, regional rights, or full commercialization. For Aktis Oncology, Inc., such deals can bring upfront cash, trial depth, and access to global sales channels.

• Co-develop lead assets
• License by region
• Expand commercial reach
• Add capital and expertise

Aktis Oncology, Inc. uses IND-enabling development to run toxicology, CMC, and regulatory work needed before first-in-human studies; as a clinical-stage company founded in 2020, it must keep advancing assets through IND milestones to move from discovery to testing in people.

This work is the bridge from lab data to human dosing, and it is the gate that determines whether a program can enter early trials.

• Toxicology
• CMC release
• IND filing

Clinical trial execution is the core proof step for Aktis Oncology, Inc., spanning first-in-human, dose-escalation, and expansion studies in patients with locally advanced or metastatic cancers and other solid tumors. It is where the company tests safety, finds a tolerated dose, and looks for early proof of concept before moving deeper into development.

• First-in-human safety readout
• Dose-escalation to set dose
• Expansion studies for signal check
• Focus on advanced solid tumors

AKY-2519 is Aktis Oncology, Inc.'s B7-H3-targeting radioconjugate for solid tumors, with development focused on prostate cancer, lung cancer, and other B7-H3-positive cancers. B7-H3 is a widely studied oncology target because it is overexpressed in many tumor types and remains a strong fit for precision radiotherapy.

• Targets B7-H3 in solid tumors
• Focuses on prostate and lung cancer
• Uses a broad, validated oncology target

Aktis Oncology, Inc. is based in Boston, Massachusetts, a major life sciences hub, and it was founded in 2020 with a rebrand in April 2020. Its key resources are a specialized clinical-stage biotech team with scientific, regulatory, and clinical expertise needed to move programs through early development.

• Boston HQ in a top biotech cluster
• Founded in 2020; rebranded April 2020
• Needs scientific, regulatory, clinical talent

Aktis Oncology is an active radiopharmaceutical developer, not just a discovery shop: it is advancing clinical-stage assets, which lowers translational risk versus preclinical-only platforms. In 2025, that shift matters because first-in-human data can de-risk target biology, dose, and safety faster than lab-only work.

• Clinical-stage pipeline, not just research
• Advancing candidates into human testing
• Lower translational risk than discovery-only assets

Aktis Oncology, Inc.’s edge is tumor-focused radiation: by concentrating dose in cancer cells and limiting exposure to healthy tissue, radiopharmaceuticals can raise efficacy while lowering off-target toxicity versus broad systemic therapy. The case is strongest with biomarker-driven patient selection, which can enrich for responders and improve the chance of meaningful benefit.

• Tumor-targeted radiation can spare healthy tissue.
• Radiopharmaceuticals are more selective than systemic therapy.
• Biomarkers can improve response and safety.

Aktis Oncology, Inc. should keep investors, the board, and the life sciences ecosystem updated on trial progress, cash use, and key milestones. For a clinical-stage company, trust and transparency drive financing continuity and help preserve strategic support between data readouts.

• Regular milestone updates
• Clear cash and runway disclosure
• Aligned board and investor trust
• Supports financing continuity

Aktis Oncology, Inc. reaches patients indirectly: oncologists refer eligible people into clinical trials, and advanced-cancer patients get access only through enrollment. That matters because trial participation still covers under 5% of adult cancer patients, so the platform’s real customer link is the physician network, while the patient is the end beneficiary.

• Physician referral drives access.
• Clinical trial enrollment mediates reach.
• Advanced-cancer patients are the end users.

Aktis Oncology, Inc. uses business development outreach to meet pharma and biotech partners directly, since platform companies depend on licensing and co-development talks to turn science into cash and reach. In 2025, oncology dealmaking stayed active, with major partners still using upfronts, milestones, and shared development costs to fund next-stage work.

• Direct pharma and biotech engagement
• Licensing and co-development focus
• Supports funding and commercialization

Aktis Oncology, Inc. uses its corporate website and investor updates to share pipeline progress, clinical milestones, and financing news. For a Boston-headquartered biotech founded in 2020, these public channels are key to building trust with investors and potential partners.

• Shares pipeline and milestone updates
• Supports investor and partner visibility
• Builds credibility for a 2020-founded biotech

Clear updates help market the company’s science, reduce information gaps, and keep stakeholders aligned on execution and value creation.

Large biopharma oncology partners are companies building radiopharmaceutical or targeted oncology pipelines, and they are the most likely licensing and co-development buyers for Aktis Oncology. These partners can fund late-stage scale-up, and in 2025-2026 radiopharma deals have stayed active because Big Pharma still needs new precision assets for the next wave of cancer launches.

• License or co-develop targeted oncology assets
• Fit for radiopharma platform partnerships
• Future commercial customer base

Payers and health systems are the groups that will judge access, reimbursement, and where Aktis Oncology, Inc. fits in care pathways. Even before launch, payer readiness matters because U.S. public programs cover over 160 million people, so proof of outcomes, patient selection, and budget impact will shape future uptake.

They will want clear data on who benefits, how long responses last, and how treatment compares on total cost of care. In oncology, health systems often decide adoption first, then payers set coverage rules, so evidence from trials and real-world use will be key.

• Access and reimbursement gate future sales.
• Outcomes data will drive coverage.
• Patient selection will matter for uptake.

GMP production, radiolabeling, validated cold chain, and radioisotope procurement are the main cost drivers. With isotopes like lutetium-177 (6.65-day half-life) and actinium-225 (9.92 days), any delay can waste product, so Aktis Oncology, Inc. must spend on tight QA and dependable supply even when it lifts overhead.

• GMP and QA drive fixed overhead
• Short half-lives raise timing risk
• Cold chain protects release value
• Supply reliability costs, but matters

Aktis Oncology, Inc., founded in 2020, still needs FDA liaison work, quality systems, legal, finance, and Boston HQ staff to support a growing pipeline. These overhead costs rise with each new program and partnership, so they can move faster than revenue in an early-stage biotech.

• FDA and quality systems drive fixed compliance cost
• Legal and finance scale with deals
• Boston headquarters adds ongoing corporate spend

Research collaboration funding at Aktis Oncology, Inc. likely comes from sponsored research and co-development deals with pharma or academic partners, helping offset discovery and translational costs for programs such as Nectin-4 and B7-H3. Aktis Oncology, Inc. has not publicly disclosed 2025/2026 collaboration revenue, so any amount should be read from deal filings or partner reports.

• Offsets discovery spend
• Supports translational work
• Often target-linked: Nectin-4, B7-H3

Aktis Oncology, Inc. has 0 approved products today, so future product sales or royalties are only a long-term option if one or more candidates clear clinical trials and FDA review. If that happens, it could sell therapies directly or collect royalties from partners, creating higher-margin revenue without building every market on its own.

• Depends on clinical success
• Needs regulatory approval
• Can monetize via sales or royalties